Get Cash Back and $0 Commissions
+ The Power of TradeStation

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Globe Newswire 4-Apr-2024 7:05 AM

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at with a replay available shortly after the live events.

About Celcuity 

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies.  Further information about Celcuity can be found at Follow us on LinkedIn and Twitter.

View source version of release on

Celcuity Inc. 
Brian Sullivan, 
Vicky Hahne, 
(763) 392-0123 

ICR Westwicke 
Maria Yonkoski,   
(203) 682-7167

Image for Press Release 1872215
Image for Press Release 1872215

Primary Logo